Skip to main content
ARROWHEAD PHARMACEUTICALS, INC. logo

ARROWHEAD PHARMACEUTICALS, INC. — Investor Relations & Filings

Ticker · ARWR ISIN · US04280A1007 LEI · 549300O3CSB8T7OZ3D66 US Manufacturing
Open in API
Filings indexed 1,039 across all filing types
Latest filing 2011-11-08 Director's Dealing
Country US United States of America
Listing US ARWR

About ARROWHEAD PHARMACEUTICALS, INC.

https://arrowheadpharma.com/

Arrowhead Pharmaceuticals, Inc. is a biotechnology company that develops medicines to treat intractable diseases by silencing the genes that cause them. The company utilizes its proprietary RNA interference (RNAi) platform to create therapies that target disease pathways previously considered 'undruggable.' Arrowhead's development pipeline is focused on a broad range of therapeutic areas, including cardiometabolic, pulmonary, neuromuscular, and liver diseases. The company advances a portfolio of clinical-stage candidates designed to address significant unmet medical needs.

Recent filings

Filing Released Lang Actions
STOCK OPTION GRANT
Director's Dealing
2011-11-08 English
FORM SC13G
Major Shareholding Notification
2011-10-28 English
FORM 8-K
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is used for current reports on significant events. The content specifically details the appointment of Dr. Bruce Given as Chief Operating Officer, including his background and compensation. This corresponds to an announcement of changes in senior management. The document is not a full annual or quarterly report, nor is it an earnings release or other financial report. Therefore, it fits the category of Board/Management Information (MANG). The document length is 4402 characters, which is consistent with a detailed announcement rather than a brief notice or a full report.
2011-10-27 English
FORM 8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content describes the company's entry into a material definitive agreement involving the sale of common stock to Lincoln Park Capital Fund, LLC, including details about the subscription agreement and the registered offering. There are no financial statements or comprehensive financial data presented, nor is this an annual or quarterly report. The primary focus is on a financing transaction (sale of shares) and related agreements. Therefore, this document fits best under the category of Capital/Financing Update (CAP). The document length is under 5,000 characters and contains substantive information about the financing event, not just an announcement of a report, so it is not an RPA or RNS.
2011-10-27 English
FORM 8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content describes entry into material definitive agreements related to financing activities, including a purchase agreement with Lincoln Park Capital Fund, preferred stock financing, and common stock financing. It details terms of these financings, registration rights, and amendments to articles of incorporation related to preferred stock. There are no financial statements or quarterly/yearly financial results presented, nor is this a transcript, proxy, or governance report. The primary focus is on capital raising and financing transactions. Therefore, the document fits best into the 'Capital/Financing Update' category (CAP). The document length is substantial and contains detailed information about financing agreements, not just an announcement or a brief note, so it is not a Regulatory Filing (RNS) or Report Publication Announcement (RPA). Confidence is high due to clear and detailed financing content.
2011-10-26 English
FINAL PROSPECTUS SUPPLEMENT
Capital/Financing Update Classification · 95% confidence The document is a 'Final Prospectus Supplement' filed pursuant to Rule 424(b)(2), describing an offering of 1,000,000 shares of common stock by Arrowhead Research Corporation. It includes detailed information about the offering, use of proceeds, business overview, and terms of the stock sale. This type of document is related to capital raising activities and financing transactions. It is not an annual or quarterly report, earnings release, or management discussion. It is a formal disclosure document for a securities offering, which fits the category of Capital/Financing Update filings. Therefore, the appropriate classification is 'CAP' (Capital/Financing Update). The document length and content confirm it is the actual prospectus supplement, not just an announcement or a brief summary, so it is not RPA or RNS. Confidence is high given the clear identification of the document as a prospectus supplement for a stock offering.
2011-10-26 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.